2. Academic Validation
  3. Evolving Treatment Landscape of HER2-mutant Non-Small Cell Lung Cancer: Trastuzumab Deruxtecan and Beyond

Evolving Treatment Landscape of HER2-mutant Non-Small Cell Lung Cancer: Trastuzumab Deruxtecan and Beyond

  • Cancers (Basel). 2023 Feb 17;15(4):1286. doi: 10.3390/cancers15041286.
Ioannis A Vathiotis 1,  Dimitrios Bafaloukos 2,  Konstantinos N Syrigos 1,  George Samonis 2
Affiliations

Affiliations

  • 1 Third Department of Internal Medicine, Sotiria General Hospital for Chest Diseases, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece.
  • 2 First Oncology Department, Metropolitan Hospital, 18547 Athens, Greece.
PMID: 36831628 DOI: 10.3390/cancers15041286
Abstract

Successful targeting of HER2-activating mutations in DESTINY-Lung02 phase II study has led to the approval of the antibody-drug conjugate (ADC) trastuzumab deruxtecan (T-DXd) as second-line treatment in patients with non-small cell lung Cancer (NSCLC). Despite the impressive results, several matters need to be addressed, including the clinical activity of T-DXd in patients with disease in the central nervous system as well as the role of T-DXd in the context of HER2 overexpression. Additionally, data regarding novel agents used to target HER2 continue to accumulate. This review highlights the challenges and unanswered questions that have emerged after the approval of T-DXd in patients with HER2-mutant NSCLC.

Keywords

HER2; NSCLC; trastuzumab.

Figures
Products